Organigram Global Inc. (NASDAQ:OGI) shares are up during Wednesday’s premarket session following the announcement of a proposed acquisition of Sanity Group, a German cannabis company.
The strategic move aims to establish Organigram as a global pure-play cannabis company with significant positions in major markets.
Deal Highlights
Organigram will pay Sanity shareholders an upfront consideration of 113.4 million euros (around $134 million), consisting of 80 million euros in cash and 33.4 million euros in Organigram shares.
In addition, Sanity shareholders will be entitled to receive up to 113.8 million euros as earnout consideration, with the first 20 million euros in cash and up to 93.8 million euros in Organigram shares.
British American Tobacco plc (NYSE:BTI) is a shareholder in both Organigram and Sanity and has opted to take Organigram share consideration instead of cash for its interest in Sanity.
Funding The Deal
The acquisition is expected to be financed by a combination of cash on hand, proceeds from a new credit facility, and expected equity investment.
Additionally, Organigram is in advanced negotiations for a 65.2 million Canadian dollar (around $47.8 million) investment from British American Tobacco to finance the cash component of the acquisition.
Strategic Rationale
“By combining our strengths as focused cannabis pure play companies, we will be well-positioned to deliver meaningful value for our shareholders and accelerate growth in key European markets,” said Paolo De Luca, Chief Strategy Officer at Organigram.
“This transformational acquisition will bring together two market leaders, extend our commercial footprint into Europe, and strengthen our competitive edge in the world’s largest federally legal cannabis markets,” said James Yamanaka, CEO of Organigram.
The acquisition is expected to be financially accretive, adding scale while supporting revenue growth and profitability, with Sanity having generated positive EBITDA in 2025.
Technical Analysis
The stock is currently trading 13.3% below its 20-day simple moving average (SMA) and 21.8% below its 100-day SMA, indicating a bearish trend in the short to medium term. Shares have decreased 6.62% over the past 12 months and are currently positioned closer to their 52-week lows than highs.
The RSI is at 31.75, which is considered neutral territory, while the MACD is below its signal line, indicating bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum.
- Key Resistance: $1.50
- Key Support: $1.00
OGI Price Action: Organigram Global shares were up 7.09% at $1.36 during premarket trading on Wednesday, according to Benzinga Pro data.
Image via Shutterstock
Recent Comments